ERSP refers Moxxor, Siglas to FTC
This article was originally published in The Tan Sheet
The Electronic Retailing Self-Regulation Program refers Moxxor, the omega-3 dietary supplement, to the Federal Trade Commission after the product's manufacturer of the same name failed to respond to an inquiry about its product, ERSP says Oct. 27. ERSP conducted a review of the firm's online advertising after receiving an anonymous complaint, and later requested substantiation for performance, endorsement, superiority and testimonial claims. ERSP also refers Siglas Inc. to the FTC for not substantiating performance and exclusivity claims for the Sauna Twin Multi-Lipo Reductor. Siglas failed to submit a "substantive response" to ERSP despite multiple requests and a 10-day deadline extension, ERSP said in a separate Oct. 27 release
You may also be interested in...
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.